Navigation Links
Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
Date:9/28/2010

induce apoptosis by down-regulating several pivotal oncogenic and tumor survival pathways.

"We are extremely pleased to have completed this financing round, which will enable Tigris to proceed with the development of our two most advanced clinical compounds," stated Edmundo Muniz, MD, PhD, Tigris' President and Chief Executive Officer, adding, "we are honored to have the support of a group of high quality investors, who have demonstrated confidence in our clinical prospects and our management team."

"I am very excited about the opportunity to invest in and lead this financing round for Tigris Pharmaceuticals," said Mr. Flanzraich. "The combination of Tigris' pipeline potential, proven leadership performance, and its vision for the future holds great promise for patients and investors."

The securities were offered to accredited investors in reliance on an exemption from the registration requirements of the Securities Act of 1993 (the "Securities Act").  The offering has not been registered under the Securities Act or any state securities or "blue sky" laws and the shares may not be offered or sold absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

About Tigris Pharmaceuticals, Inc

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology and other human diseases.  Tigris is currently initiating a Phase II trial for AFP-464, a novel anticancer agent in patients with breast cancer and is also conducting a multi-center Phase I dose escalation study for GGTI-2418, another first-in-class agent, at Abramson Cancer Center at The University of Pennsylvania and Indiana University Melvin and Bren Simon Cancer Center.  

With a management team that has a proven track record in guiding molecules from the early stages of clinical development to successful
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
2. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
3. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...   MultiVir Inc. ("MultiVir"), a clinical-stage gene ... for the treatment of multiple oncological indications, today announced ... Form S-1 with the U.S. Securities and Exchange Commission ... shares of its common stock. The number of shares ... proposed offering have not yet been determined. MultiVir has ...
(Date:3/30/2015)... Sorrento Therapeutics, Inc. (Nasdaq: SRNE ) ... to the position of Executive Vice President & ... be responsible for all legal, compliance and intellectual property ... BioDelivery Sciences International, Inc., where he was Senior Vice ... management that led that company to over a six ...
(Date:3/30/2015)... Mass. , March 30, 2015 Alere ... rapid diagnostics, issued the following statement today in support ... to Combat Antibiotic-Resistant Bacteria. "As the ... commend President Barack Obama for establishing a ... to address the serious threat of antibiotic resistance. We ...
Breaking Medicine Technology:MultiVir Files Registration Statement for Proposed Initial Public Offering 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3Alere Applauds President's National Action Plan to Combat Antibiotic-Resistant Bacteria 2
... 19, 2007 /PRNewswire-FirstCall/ --,Allos Therapeutics, Inc. today ... with a favorable opinion of the Committee ... Agency (EMEA),has granted orphan drug designation to ... treatment of patients with,peripheral T-cell lymphoma (PTCL). ...
... -- Median time to pain progression is 66.1 ... for the placebo arm --,Hazard ratio of 0.64 ... the relative risk of pain progression, MARTINSRIED/MUNICH, Germany, ... Colo. -- GPC Biotech AG and,Pharmion Corporation today ...
Cached Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6
(Date:3/30/2015)... (PRWEB) March 30, 2015 Hosted by ... the CDA Cares free, two-day dental clinic in Sacramento ... people March 27-28. , In addition to providing ... who experience barriers to care, CDA Cares educates the ... health and the need for an adequately funded dental ...
(Date:3/30/2015)... With the summer dry season approaching, residents ... to make sure they have enough water. Fresh water ... that when Earth loses water and becomes dehydrated, the ... Kleyne calls this “body drought” and suggests several ways ... body drought and dehydration on her Sharon Kleyne Hour™ ...
(Date:3/30/2015)... Healtheminds, a start-up focusing on providing high ... easy to use and engaging online platform, is launching ... health related issues. The first in the series is ... other drugs. , Consumption and use of alcohol ... the toxic effects of excessive intake or drug overdoses, ...
(Date:3/30/2015)... OH (PRWEB) March 30, 2015 Wright ... product liability lawsuits, notes that the number of ... multidistrict litigation underway in U.S. District Court, District of ... in December 2014. "According to an update released by ... March 16th, at least 493 Syngenta lawsuits are now ...
(Date:3/30/2015)... Birmingham, AL (PRWEB) March 30, 2015 ... medical malpractice and defective medical devices, has filed a ... Alabama family whose baby died following his premature birth ... Mobile County Circuit Court, alleges that the Mirena IUD ... strings, which also made the device difficult to remove. ...
Breaking Medicine News(10 mins):Health News:CDA Cares Sacramento Dental Clinic Provides $2 Million in Care 2Health News:As California Dry Season Approaches, Risk of Body Drought Increases, Warns Fresh Water Advocate 2Health News:As California Dry Season Approaches, Risk of Body Drought Increases, Warns Fresh Water Advocate 3Health News:HealthEminds Launching Webinar on Drug Dependence 2Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 2Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 3Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 2Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 3Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 4
... In its ongoing contribution to science and the innovation of industry leading ... (R) ... r (TM) ... Eniva,s newest heart health product, designed to support healthy cholesterol and homocysteine ...
... perform at similar level as those without reconstruction , ... Las Vegas, ... American Orthopaedic Society of Sports Medicine Specialty Day in Las ... in the Major League Baseball (MLB) draft does not increase the risk ...
... vSling for capturing and distributing patient testimonials on ... will highlight their newest practice-to-patient communication feature, vSling, ... Attracting thousands of dental practitioners annually, the Midwinter ... Reminder to show its revenue boosting communication service ...
... (NYSE: BKD ) announced today that the Company ... Restated Credit Agreement. The amended credit agreement consists of ... 2010. Additionally, the Company announced that it has recently ... to $48.5 million in the aggregate. The letter of ...
... Rankin Shapiro, PhD, have collaborated for 20 years to ... Barrow Neurological Institute at St. Joseph,s Hospital and Medical ... the Shapiros have established a $1.5 million endowed chair ... represents our desire to give back and will allow ...
... & Hair Replacement Center, Hair Fantasy, LLC is now offering new ... hair or baldness. , ... Greenbelt, MD (PRWEB) February ... may be attributed to chemotherapy from cancer, burn trauma, alopecia, male ...
Cached Medicine News:Health News:New Innovation for Battling Number One Killer in America Introduced by Eniva Nutraceutics 2Health News:New Innovation for Battling Number One Killer in America Introduced by Eniva Nutraceutics 3Health News:New Innovation for Battling Number One Killer in America Introduced by Eniva Nutraceutics 4Health News:New Innovation for Battling Number One Killer in America Introduced by Eniva Nutraceutics 5Health News:Elbow Ligament Reconstruction Appears Not to Effect Future Professional Advancement in Baseball 2Health News:Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Society's Midwinter Meeting 2Health News:Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Society's Midwinter Meeting 3Health News:Brookdale Amends and Extends Corporate Line of Credit 2Health News:Brookdale Amends and Extends Corporate Line of Credit 3Health News:A lifetime of paying it forward 2Health News:Inspired Cancer Survivor Launches Customized Hair Replacement ,Techniques at Award-Winning Hair Salon 2
... Restylane is a ... generated by,Streptococcus species of ... stabilized and suspended in ... = 7 and concentration ...
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
Minimizes imperfections and reduces the visible appearance of cellulite and stretch marks. This formula refines uneven skin texture and improves skin firmness and elasticity to leave you with skin yo...
... delivers clinically proven aminophylline directly to the ... fat reduction with the aminophylline containing cream ... an increase in the firmness of the ... the skin where it causes the body ...
Medicine Products: